Kornimate/medical-research-clean huggingface dataset:
outcome prediction in patients with aortic stenosis after tavi

Conditions: Aortic Stenosis, Severe

Summary: this study will investigate changes right ventricular function and functional recovery metrics after transcatheter aortic valve implantation

aortic stenosis (as), is a condition in which the aortic valve becomes narrowed as people get older, causing the heart pump (the left ventricle) to struggle to push blood through it, leading to breathlessness, chest pain and blackouts. if left untreated, the prognosis is bleak (similar to lung cancer). previously the only effective treatment for as was a valve replacement via open heart surgery, which was too high risk for many patients to undergo, meaning they were left without treatment. over the last decade transcatheter aortic valve implantation (tavi) has emerged as a treatment option for most patients with severe symptomatic as. in tavi, a new valve is inserted through a small tube, usually in the leg artery, which avoids open heart surgery. clinical outcomes after tavi have significantly improved with the accumulation of operator and institution experience as well as the wide use of newer generation devices. however, a significant minority of patients undergoing tavi derive little or no benefit from the procedure. nearly a third describe no improvement in quality of life, or die within the first year. to combat this problem, it is essential we develop more sophisticated means of predicting adverse outcomes related to tavi, to improve the selection of patients and identify patients where the potential benefit of the procedure is outweighed by unfavourable outcomes. assessment of physical recovery and improvement of symptoms and quality of life after tavi is an important aspect of examining the outcomes of treatment. this is often a more meaningful and relevant treatment goal in the tavi cohort than 'hard' clinical outcomes (like death and stroke) alone. traditionally, less emphasis has been put on the assessment of the right side of the heart (the right ventricle) in evaluating physical recovery after tavi. we propose prospective observational study to evaluate the significance of the right side of the heart on the clinical outcomes related to functional recovery in patients undergoing tavi.

Eligibility criteria:
inclusion criteria: * patients with symptomatic severe aortic stenosis (ava \ 40mmhg or jet velocity \>4.0 m/s). exclusion criteria: * extracardiac limitations of ambulatory exercise, cardiac rehab opt out, non-transfemoral tavi, haemodynamic instability/cardiogenic shock, lvef \<40%, poorly controlled af, severe copd, primary pulmonary hypertension, evidence of cardiac amyloid, more than moderate concomitant valvular heart disease other than aortic stenosis, previous sternotomy, permanent pacemaker implant, patients enrolled in another study where participation would involve deviation from either protocol.
comparative effect of scaphoid, hamate mobilization and neural mobilization in patients with carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: to rule out the effects bone mobilization and neural mobilization in carpal tunnel syndrome.

a randomized control study of 3 month period will be conducted at riphah international university faisalabad. patients will be enrolled by purposive sampling based on pre-defined inclusion and exclusion criteria. patients were randomly allocated into groups. the patients of group a will receive scaphoid, hamate mobilization with kinesio taping and group b will receive neural mobilization with kinesiotaping. group a will receive neural mobilization and group b will receive scaphoid and hamate moilization. the patient's outcome will be distinguished by visual analogue scale and the data of the patients will be noted pre-treatment and post-treatment. informed consent will be taken from each patient. data entry and analysis will prepare through statistical package of social sciences version 20.

Eligibility criteria:
inclusion criteria: * at median nerve distribution, felt pain and parasthesia phalen sign positive tinel sign positive increase symptoms throughout the night symptoms that continue for at least 3 weeks exclusion criteria: * pregnancy diabetes thyroid disease rheumatoid arthritis thenar muscle atrophy weakness of thenar muscle hand surgery/ bone fracture
neck joint position error among taibah students university; saudi arabia; cross section design

Conditions: Proprioception

Summary: this study was done to answer the following: is there a difference between students without and with varying degrees of text neck in cervical proprioception defect? is there a correlation between jpe and severity of text neck among taibah students university?


Eligibility criteria:
inclusion criteria: * a convenient sample of 68 female students * the age was between 18-25 years exclusion criteria: * any students with neck pain or previous neck or back surgery or a history of a previous accident were excluded * also, we excluded any student with a history of fracture injury of the cervical column, scoliosis, severe thoracic kyphosis, rheumatic disease, torticollis, loss of standing balance, use of hearing aid, and persistent respiratory problems.
progressive tension sutures in gender affirming mastectomy

Conditions: Hematoma; Seroma

Summary: 50 patients seeking gender affirming mastectomy will be treated with different closure techniques in each side of their chest - one side will receive progressive tension sutures between pectoral fascia and the mastectomy flap, and the other side will not. both sides will have drains in the mastectomy site. rates of hematoma, seroma, and other complications will be compared between each chest side via standard statistical techniques for hypothesis testing.


Eligibility criteria:
inclusion criteria: 1. being consulted for gender affirming mastectomy with the senior author (ah). 2. \>18 years of age at the time of enrollment. 3. transgender or gender nonbinary gender identity. 4. all co-morbidities and all indications. exclusion criteria: 1. age less than 18 years. 2. bmi \< 23.

Keywords: mastectomy
a study of the effect of cj-023,423 on the incidence of stomach ulcers

Conditions: Osteoarthritis

Summary: cj-023,423 is a new medication being developed as an anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (oa). the purpose of this study is to evaluate whether patients treated with cj-023,423 for 7 days (14 doses) have fewer gastrointestinal ulcers compared to patients treated with naproxen and placebo.


Eligibility criteria:
inclusion criteria: * is a healthy adult 18 to 75 years of age, inclusive; healthy is defined as no clinically relevant abnormalities identified as detailed medical history, full physical examination, including blood pressure \[bp\] and pulse rate \[pr\]measurement, 12-lead electrocardiogram \[ecg\], and clinical safety laboratory tests * if female and of childbearing potential (includes women who have been postmenopausal for \< 2 years ), must be using adequate contraception, must not be lactating and must have had a negative serum pregnancy test at screening and a negative urine pregnancy test result within 24 hours prior to receiving study drug. the site investigator must ensure that female subjects are not pregnant prior to receiving the first dose of drug; exclusion criteria: * endoscopic evidence of inflammation, ulceration, erosion, petechiae, or active bleeding in the esophagus, stomach, pyloric channel, or duodenum at the baseline/ randomization (day 1) endoscopy (mucosal grading scale score \>0); * active gi disease (e.g. inflammatory bowel disease), a history of gastroduodenal ulcers or bleeding, or a history of any gastric or duodenal surgery;
a study to compare fkb327 long-term safety, efficacy and immunogenicity with humira® in rheumatoid arthritis patients

Conditions: Arthritis, Rheumatoid

Summary: the purpose of the study is to compare the long-term safety, effectiveness and immunogenicity of fkb327 in comparison to humira® in rheumatoid arthritis patients who have completed study fkb327-002 and have inadequate disease control on methotrexate.

the first period of this extension study was an open label, randomised, comparative, multi centre, 2 arm extension phase 3 study in patients with ra who were taking a stable dose of mtx and who had continued from the preceding study fkb327-002 (nct02260791). the transition from study fkb327-002 was ideally to occur without interruption: the week 24 visit of study fkb327-002 was to be on the same day as the week 0 visit of study fkb327-003. patients who had received fkb327 in study fkb327-002 received fkb327 or humira in a 2:1 ratio and patients who had received humira in study fkb327-002 received humira or fkb327 in a 2:1 ratio (period i). the second period of the study was an open label, single arm extension in which all patients received fkb327 treatment from week 30 to week 76 (period ii), followed by a 4 week follow up period. clinic visits were scheduled for weeks 0, 2, 4, 8, 12, 24, 30, 32, 34, 42, 54, 66, 76, and 80. the patient or carer was allowed to administer interim doses of study drug at home every other week (eow) between clinic visits.

Eligibility criteria:
inclusion criteria: 1. patient has completed the week 24 visit procedures of study fkb327-002 (nct02260791) and are continuing with methotrexate 2. in the investigator's opinion, the patient showed a clinical response to treatment during study fkb327-002 (nct02260791) exclusion criteria: 1. patient has evidence of a serious adverse event (sae) ongoing from study fkb327-002 2. patient has presence of active and/or untreated latent tuberculosis (tb) other inclusion/exclusion criteria may apply.

Keywords: rheumatoid arthritis
selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates

Conditions: Ductal Carcinoma in Situ

Summary: this study aimed to assess the prevalence of upgrade to invasive breast cancer and axillary lymph node metastasis in patients who were diagnosed with dcis on biopsy and subsequently underwent mastectomy with axillary surgery to establish the need for slnb. furthermore, we explored the clinicopathologic features related to the upgrade to invasive breast cancer and axillary lymph node metastasis.


Eligibility criteria:
inclusion criteria: 1. women diagnosed with dcis in preoperative biopsy samples obtained by core needle biopsy, vacuum-assisted breast biopsy, or excisional biopsy 2. women underwent curative surgery for dcis exclusion criteria: 1. patients who received breast-conserving surgery 2. patients who had concurrent contralateral invasive breast cancer 3. patients who were in case of ipsilateral breast tumor recurrence 4. patients whose invasiveness was uncertain in the biopsy samples
laparoscopic occlusion of uterine vessels compared to uterine fibroid embolization for treatment of uterine fibroids

Conditions: Uterine Fibroids

Summary: women with symptomatic uterine fibroids are treated either by uterine fibroid embolization (ufe) or laparoscopic occlusion. the study hypothesis is that laparoscopic occlusion of uterine vessels and ufe have equal effect on bleeding symptoms. menstrual bleeding reduction six months after treatment is the main endpoint. secondary endpoints include participants assessment of symptom relief, and volume reduction of fibroids measured by mri. we will also investigate possible differences in postoperative course, symptom reduction, complication, and recurrence. patients are controlled with regular intervals up to five years after treatment.

uterine fibroid embolization (ufe)has become an alternative to hysterectomy for women with symptoms of uterine fibroids.follow up studies of this new method have reported relief of menstrual bleeding by 85-90 % of the patients six to twelve months after treatment.other studies have suggested laparoscopic bilateral occlusion of uterine arteries as an equal effective alternative, but to our knowledge there is no randomized studies published. patients recruitment : women with symptoms of uterine fibroids referred to the clinic,who express a desire to avoid hysterectomy. study hypothesis: laparoscopic occlusion of uterine vessels and ufe have equal effect on bleeding symptoms. gynecological examination, ultrasonography and magnetic resonance imaging (mri) are performed preoperatively and after 1,3 and 6 months. clinical follow up is planned after 1,3,6,12,24,36 and 60 months.a validated bleeding chard, pictorial blood assessment chart(pbac)is filled in by the participants during the last menstruation period before treatment and before each control. a standardized questionnaire to assess the bleeding amount,pressure symptoms, pain, adverse events, other complains and patients satisfaction is also used.

Eligibility criteria:
inclusion criteria: * menorrhagia and/or bulk symptoms associated with uterine fibroids exclusion criteria: * malignancy * current or planned pregnancy * small submucous fibroids suitable for hysteroscopic resection * postmenopausal women * suspected or known adenomyosis * uterus size exceeding the umbilical level * contraindications against laparoscopic surgery

Keywords: uterine fibroids leiomyoma laparoscopy menorrhagia
evaluation of endobronchial ultrasound (ebus) for staging lung cancer

Conditions: Lung Cancer

Summary: this study will compare two different methods of staging lung cancer to determine whether endobronchial ultrasound (ebus) staging of mediastinal lymph nodes will provide good diagnostic yield in detecting lung cancer, when compared to current methods of a staging bronchoscopy and cervical mediastinoscopy.


Eligibility criteria:
inclusion criteria: patients, \> 18 years of age, gender- males and female diagnosis of non small cell lung cancer. patients who have consented on an ottawa hospital consent form to undergo a mediastinoscopy procedure or ebus-tbna, and a positron emission tomography (pet) of the chest for lung cancer staging. exclusion criteria: females who are pregnant (or found to be pregnant) during the course of this research study. patients who do not provide their ottawa hospital consent to undergo a staging bronchoscopy , cervical mediastinoscopy or ebus-tbna.

Keywords: lung cancer cervical mediastinoscopy endobronchial ultrasound staging
low molecular weight heparin in prevention of recurrent arteriovenous graft thrombosis in chronic hemodialysis patients.

Conditions: Hemodialysis Patients

Summary: the aim of the study is to evaluate the effect of enoxaparin (lmwh) on the incidence of av graft thromboses in patients on chronic hemodialysis. primary efficacy end point of the study: to compare the time of onset of a new thrombotic event after successful angiography of the av graft. pprimary safety outcome of the study: frequency of hemorrhage. design and methods: following a first av graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c enoxaparin (clexane) 0.5 mg/1kg of body weight per day or control group (not on clexane). patients will be followed for a year or till next av graft thrombotic occlusion, if it occurs before. in both groups we will compare time periods in months between first and recurrent thrombotic events of avg by evaluation the difference between two sample means. also interim analysis of av grafts patency between the two groups will be evaluated at different time points: three, six and twelve months after randomization. patients in both groups will receive unfractionated heparin during dialysis session to prevent thrombosis of extracorporeal circulation. patients from enoxaparin group will receive a half dose (500 units/hour) to prevent possible risk of bleeding during the session. before randomization all patients will be evaluated for hypercoagulability state which will include: factor v laden deficiency, anti phospholipid antibodies (apla), antithrombin iii deficiency and protein c/s deficiency.


Eligibility criteria:
inclusion criteria: * hemodialysis patients ≥ 18 years of age after occurrence of avg thrombosis and successful thrombolysis/thrombectomy with angioplasty. exclusion criteria: 1. known allergy to enoxaparin 2. persistent systolic blood pressure 180 or more and/or persistent diastolic blood pressure 100 or more 3. chronic warfarin treatment 4. double antiagregant treatment (aspirin plus clopidogrel) 5. platelets count below 80000/µl 6. known hit (heparin induced thrombocytopenia) 7. recent bleeding (\<2 weeks) 8. recent stroke (\<4 weeks) 9. reduced mental status and inability to give informed consent
cardiovascular disease knowledge/morbidity--socioeconomic cohort outcomes

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to elucidate the interrelationship of level of cardiovascular disease knowledge and subsequent clinical health status by merging population-based cardiovascular disease risk factor survey data with patient-level hospital data. the overall goal was to assess outcomes in the positive/negative association between level of cardiovascular disease knowledge and incidence and relative degree of morbidity among a cohort with and without major cardiovascular disease risk factors.

background: evidence shows a growing disparity in the prevalence of modifiable risk factors and incidence of cardiovascular disease between upper and lower socioeconomic status (ses) individuals. trends in knowledge about risk factors and risk reduction strategies parallel these findings. research determining the differential association between level of cardiovascular disease knowledge and subsequent clinical health status had not been conducted. design narrative: analyses were stratified according to ses (via years of formal education), controlling for age, gender, and ethnicity (latino/anglo). sociodemographic, physiologic, and knowledge measurements were available on each participant. morbidity estimates and clinical health status indicators were available via primary and secondary discharge diagnostic codes from public-use hospital discharge databases collected on all california hospital admissions for the entire study period. the stanford five city program data were merged with the hospital discharge data, matching on survey participant's social security number which was subsequently converted to a unique personal identifier. baseline 1989/90 and 1991 through 1995 longitudinal outcomes were assessed. there were three main aims, all of which had epidemiologic and cardiovascular disease health policy prevention implications: aim 1: characterize the distribution of hospitalized versus non-hospitalized ses sub-cohorts according to level of c.d. knowledge, physiologic risk factor prevalence, and clinical morbidity prevalence. aim 2: test the hypothesis that morbidity differences between hospitalized ses sub-cohorts would vary as a function of baseline level of cardiovascular disease knowledge and risk factor prevalence. aim 3: test the hypothesis that morbidity would rise among hospitalized lower ses sub-cohorts, resulting in widening health status disparities by the end of the study period. parametric and nonparametric analytic methods were used, including analysis of variance and covariance, and various regression techniques. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
antistax® in patients with chronic venous insufficiency

Conditions: Venous Insufficiency

Summary: study to determine the efficacy and tolerability of two dose levels of antistax relative to placebo in patients suffering from cvi grade i or incipient grade ii


Eligibility criteria:
inclusion criteria: * male or female * between 25 and 75 years of age * cvi i or cvi ii (without expanded trophic disturbances) * willing and able to give written informed consent prior to participation in the study exclusion criteria: concomitant disease(s) exclusion criteria: * decompensated cardiac insufficiency * edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc) * peripheral arterial disease (ankle/arm pressure index \< 0.9) * current acute phlebitis or thrombosis * renal insufficiency (serum creatinine \> 1.5 mg/dl) * liver disease (sgpt (alat) \> 3x upper limit of normal) * other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies * anamnestic indications of diabetic microangiopathy or polyneuropathy * drug and/or alcohol abuse * severe climacteric complaints * immobility * avalvulia * klippel-trénaunay-weber-syndrome (naevus varicosis osteohypertrophicus, haemangiectasia hypertrophicans) * state after pulmonary embolism * recognized hypersensitivity to the trial drug ingredients * current florid venous ulcus * clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc. previous treatment(s) exclusion criteria: * treatment with venous drugs within the last 4 weeks * treatment with laxatives which affect fluid or electrolyte balance within the last 8 days * changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ace inhibitors or calcium antagonists within the last 8 days * changes in post-menopausal hormone replacement within the last 2 months concomitant treatment/non-drug therapy exclusion criteria: * other venous drugs apart from the trial medication * compression therapy * venous surgery at the leg(s) * extensive use (on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance * major surgery requiring full anesthesia other exclusion criteria: * previously studied under this protocol * participation in another clinical trial within the previous 90 days or during the present study * patients who have visited a sauna or had other thermal applications in the previous day before any visit * pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only) * patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial * patients in a bad general health state according to the investigator's judgment